A Guth Labs publication ↗
Back to News

Recursion reports FDA agreement on Phase 3 design for AI-enabled drug program

Green glass molecular structure above a cream pedestal surrounded by a translucent spiral pathway with a gold accent.
AI-generated editorial illustration

Recursion said on November 18 that it had aligned with the US Food and Drug Administration on the design of a Phase 3 trial for REC-4881, an investigational treatment for familial adenomatous polyposis. The company expects the trial to begin in the second half of 2027. Company announcement

The randomized, blinded, placebo-controlled study is expected to enroll about 200 adults who have already undergone surgery to remove the colon, or the colon and rectum. Its primary measure combines several events, including removal of adenomas at least 10 millimeters across, certain surgeries, advanced precancerous changes, cancer or death.

Recursion says its AI-based screening identified the drug's potential for this inherited condition. That makes the update a clinical-development milestone for an AI-enabled program, not the launch of a new AI model.

REC-4881 remains under investigation in the ongoing TUPELO study. Agreement on a trial design is not approval to market the drug, and it does not establish that the planned study will succeed.

The next test is whether the program can demonstrate meaningful benefits in a controlled late-stage trial, beyond the earlier evidence used to design it.

Sources and citations

Revision history

Published .